Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Clinical Study for Evaluating the Safety and Efficacy of FKC876 in the Treatment of Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

Next Previous
Trial Profile

An Open-Label Clinical Study for Evaluating the Safety and Efficacy of FKC876 in the Treatment of Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axicabtagene ciloleucel (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Fosun Kite Biotechnology

Most Recent Events

  • 27 Oct 2022 According to a Fosun Kite Biotechnolog media release, due to this NDA application, adult patients suffering from large B cell lymphoma and not responding to first-line immunochemo therapy or relapsing within 12 months after first-line immunochemo therapy are expected to enjoy such benefits earlier.
  • 27 Oct 2022 According to a Fosun Kite Biotechnolog media release, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its NDA filing of the company's CAR-T as a second-line therapy for large B cell lymphoma. One year ago, YIKAIDA, was approved for third-line use in the same disease. The NDA was approved for the review and included in the list for priority review.
  • 23 Jun 2021 Results presented in a Fosun Kite Biotechnology media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top